Sands Capital Discloses 6.3% Stake in Alamar Biosciences Post-IPO

summarizeSummary

Sands Capital has reported a substantial 6.3% ownership in Alamar Biosciences, Inc. following its IPO, demonstrating significant institutional backing for the new public entity.

check_boxKey Events

• Major Institutional Stake Established

  Sands Capital Life Sciences Pulse Fund II, L.P. reported a 6.3% beneficial ownership of Alamar Biosciences' common stock, totaling 4,230,926 shares.

• Post-IPO Investment

  The stake was primarily acquired through the conversion of pre-IPO preferred stock and a convertible note, along with a direct purchase of 300,000 shares at the IPO price of $17.00 per share.

• Board Representation

  An Executive Managing Partner from Sands Capital, Ian Ratcliffe, serves on the Issuer's board of directors, indicating active involvement.

auto_awesomeAnalysis

Sands Capital Life Sciences Pulse Fund II, L.P. has disclosed a significant 6.3% beneficial ownership stake in Alamar Biosciences, Inc. following its recent initial public offering. This stake, valued at approximately $71.9 million based on the IPO price, or over $100 million at the current market price, signals strong institutional confidence in the newly public company. The investment firm's Executive Managing Partner also holds a board seat, indicating active engagement and a long-term commitment.